Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus
Cardiovascular (CV) morbidity and mortality are a challenge in management of patients with systemic lupus erythematosus (SLE). Higher risk of CV disease in SLE patients is mostly related to accelerated atherosclerosis. Nevertheless, high prevalence of traditional cardiovascular risk factors in SLE p...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2018/3424136 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849467527852195840 |
|---|---|
| author | Alberto Floris Matteo Piga Arduino Aleksander Mangoni Alessandra Bortoluzzi Gian Luca Erre Alberto Cauli |
| author_facet | Alberto Floris Matteo Piga Arduino Aleksander Mangoni Alessandra Bortoluzzi Gian Luca Erre Alberto Cauli |
| author_sort | Alberto Floris |
| collection | DOAJ |
| description | Cardiovascular (CV) morbidity and mortality are a challenge in management of patients with systemic lupus erythematosus (SLE). Higher risk of CV disease in SLE patients is mostly related to accelerated atherosclerosis. Nevertheless, high prevalence of traditional cardiovascular risk factors in SLE patients does not fully explain the increased CV risk. Despite the pathological bases of accelerated atherosclerosis are not fully understood, it is thought that this process is driven by the complex interplay between SLE and atherosclerosis pathogenesis. Hydroxychloroquine (HCQ) is a cornerstone in treatment of SLE patients and has been thought to exert a broad spectrum of beneficial effects on disease activity, prevention of damage accrual, and mortality. Furthermore, HCQ is thought to protect against accelerated atherosclerosis targeting toll-like receptor signaling, cytokine production, T-cell and monocyte activation, oxidative stress, and endothelial dysfunction. HCQ was also described to have beneficial effects on traditional CV risk factors, such as dyslipidemia and diabetes. In conclusion, despite lacking randomized controlled trials unambiguously proving the protection of HCQ against accelerated atherosclerosis and incidence of CV events in SLE patients, evidence analyzed in this review is in favor of its beneficial effect. |
| format | Article |
| id | doaj-art-e702097f735c45a7a5e04e142b108b8e |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-e702097f735c45a7a5e04e142b108b8e2025-08-20T03:26:10ZengWileyMediators of Inflammation0962-93511466-18612018-01-01201810.1155/2018/34241363424136Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus ErythematosusAlberto Floris0Matteo Piga1Arduino Aleksander Mangoni2Alessandra Bortoluzzi3Gian Luca Erre4Alberto Cauli5Rheumatology Unit, University Clinic and AOU of Cagliari, Monserrato, ItalyRheumatology Unit, University Clinic and AOU of Cagliari, Monserrato, ItalyDepartment of Clinical Pharmacology, College of Medicine and Public Health, Flinders University and Flinders Medical Centre, Adelaide, AustraliaDepartment of Medical Sciences, Section of Rheumatology, University of Ferrara and Azienda Ospedaliero-Universitaria Sant’Anna di Cona, Ferrara, ItalyRheumatology Unit, Department of Clinical and Experimental Medicine, University Hospital (AOUSS) and University of Sassari, Sassari, ItalyRheumatology Unit, University Clinic and AOU of Cagliari, Monserrato, ItalyCardiovascular (CV) morbidity and mortality are a challenge in management of patients with systemic lupus erythematosus (SLE). Higher risk of CV disease in SLE patients is mostly related to accelerated atherosclerosis. Nevertheless, high prevalence of traditional cardiovascular risk factors in SLE patients does not fully explain the increased CV risk. Despite the pathological bases of accelerated atherosclerosis are not fully understood, it is thought that this process is driven by the complex interplay between SLE and atherosclerosis pathogenesis. Hydroxychloroquine (HCQ) is a cornerstone in treatment of SLE patients and has been thought to exert a broad spectrum of beneficial effects on disease activity, prevention of damage accrual, and mortality. Furthermore, HCQ is thought to protect against accelerated atherosclerosis targeting toll-like receptor signaling, cytokine production, T-cell and monocyte activation, oxidative stress, and endothelial dysfunction. HCQ was also described to have beneficial effects on traditional CV risk factors, such as dyslipidemia and diabetes. In conclusion, despite lacking randomized controlled trials unambiguously proving the protection of HCQ against accelerated atherosclerosis and incidence of CV events in SLE patients, evidence analyzed in this review is in favor of its beneficial effect.http://dx.doi.org/10.1155/2018/3424136 |
| spellingShingle | Alberto Floris Matteo Piga Arduino Aleksander Mangoni Alessandra Bortoluzzi Gian Luca Erre Alberto Cauli Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus Mediators of Inflammation |
| title | Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus |
| title_full | Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus |
| title_fullStr | Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus |
| title_full_unstemmed | Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus |
| title_short | Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus |
| title_sort | protective effects of hydroxychloroquine against accelerated atherosclerosis in systemic lupus erythematosus |
| url | http://dx.doi.org/10.1155/2018/3424136 |
| work_keys_str_mv | AT albertofloris protectiveeffectsofhydroxychloroquineagainstacceleratedatherosclerosisinsystemiclupuserythematosus AT matteopiga protectiveeffectsofhydroxychloroquineagainstacceleratedatherosclerosisinsystemiclupuserythematosus AT arduinoaleksandermangoni protectiveeffectsofhydroxychloroquineagainstacceleratedatherosclerosisinsystemiclupuserythematosus AT alessandrabortoluzzi protectiveeffectsofhydroxychloroquineagainstacceleratedatherosclerosisinsystemiclupuserythematosus AT gianlucaerre protectiveeffectsofhydroxychloroquineagainstacceleratedatherosclerosisinsystemiclupuserythematosus AT albertocauli protectiveeffectsofhydroxychloroquineagainstacceleratedatherosclerosisinsystemiclupuserythematosus |